Genmab Announces Multiple Abstracts to be Presented at the 65th Annual Meeting and Exposition of the

Eighteen total abstracts accepted for presentation and publication, including results from four clinical trials evaluating epcoritamab in multiple treatment settings and patient populationsOral presentations highlighting new findings from a clinical trial of epcoritamab in patients with relapsed/refractory (R/R) dif...

Related Keywords

Japan ,San Diego ,California ,United States ,New Jersey ,Netherlands ,Canada ,Copenhagen ,Køavn ,Denmark ,Tokyo ,United Kingdom ,American ,Hematol Hemoter ,David Freundel ,Andrew Carlsen ,Judith Klimovsky ,Exchange Commission ,Lymphoma Research Foundation ,Company Announcement ,Twitter ,Outcomes Research ,National Comprehensive Cancer Network ,Abbvie Biotechnology Ltd ,American Society Of Hematology ,Discovery Research ,Exposition Of The American Society Hematology ,Global Communications Corporate Affairs ,Data From The Observational National Lymphocare Study ,European Union ,Genmab Us Inc ,Annual Meeting ,American Society ,Executive Vice President ,Chief Development Officer ,Epcoritamab Plus Lenalidomide ,Patients With ,Refractory Diffuse Largeb Cell Lymphoma ,Drives Deep ,Durable Responses ,Refractory Follicular Lymphoma ,Preliminary Results ,Subcutaneous Epcoritamab With Rituximab ,Patients With Relapsed ,Refractory Follicular ,Gemox Leads ,High Complete Metabolic Response Rates ,Cell Lymphoma Ineligible ,Autologous Stem Cell Transplant ,Updated Results ,Optimal Dosing Regimen ,Subcutaneous Epcoritamab ,Refractoryb Cell Non Hodgkin ,Full Dose Anthracycline ,Naive Patients ,Refractory Multiple Myeloma ,Dose Expansion Cohort ,Novel Therapies ,Later Line ,Aggressive Largeb Cell Lymphoma ,World Response Rates Across Lines ,Therapy Among Patients With ,Resource Use Among Elderly ,Refractory Follicular Lymphoma Patients ,Efficiency Associated ,Unraveling Genomic ,Transcriptomic Features ,Precision Medicine ,Targeted Therapies ,Largeb Cell Lymphoma ,Diffuse Largeb Cell Lymphoma ,Follicular Lymphoma ,National Comprehensive Cancer ,Clinical Practice Guidelines ,Medication Guide ,Annual Report ,Y Shaped Genmab ,Abbvie Biotechnology ,Largeb Cell ,Rev Oncol ,Western Europe ,Lymphoma Research ,Accessed October ,Opin Med ,Bras Hematol ,Subsequent Therapy ,Data From ,Observational National Lymphocare ,Economic Burden ,Treatment Patterns ,Patients With Diffuse Largeb Cell Lymphoma ,Senior Director ,Global Communications ,Corporate Affairs ,Vice President ,Investor Relations ,